U.S. markets close in 28 minutes

Cynata Therapeutics Limited (CYYNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.46500.0000 (0.00%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4650
Open0.4650
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4650 - 0.4650
52 Week Range0.3500 - 0.7600
Volume2,000
Avg. Volume1,200
Market Cap43.868M
Beta (5Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)-0.0390
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
    Simply Wall St.

    We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers
    GlobeNewswire

    Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers

    Key highlights Ethics approval received for clinical trial in patients with diabetic foot ulcers First clinical trial to utilise the wound dressing technology recently licensed from TekCyte Patient recruitment expected to commence in 2H CY21 MELBOURNE, Australia, June 30, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by th

  • Cynata signs Licence Agreement with TekCyte to advance Clinical Trial in Diabetic Foot Ulcers
    GlobeNewswire

    Cynata signs Licence Agreement with TekCyte to advance Clinical Trial in Diabetic Foot Ulcers

    MELBOURNE, Australia, June 03, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a worldwide exclusive licence agreement with TekCyte Pty Ltd (TekCyte) in respect of TekCyte’s wound dressing technology. Cynata has also secured an option to purchase the relevant technology outright. Key highlights Secured worldwide exclusive licence agreement